Premium
Micafungin for candidiasis
Author(s) -
Pappas Peter G.
Publication year - 2012
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2011.02112.x
Subject(s) - micafungin , echinocandins , invasive candidiasis , echinocandin , antifungal , intensive care medicine , medicine , esophageal candidiasis , candida infections , microbiology and biotechnology , biology , immunology , amphotericin b , caspofungin , fluconazole , human immunodeficiency virus (hiv) , viral disease
Summary Invasive candidiasis and mucosal candidiasis are among the most important health care associated infections; in its invasive form, candidiasis is associated with substantial morbidity and mortality. Among the currently available antifungal agents, the echinocandins are the among the most potent agents against Candida species. As a class, these agents are well tolerated and rapidly fungicidal. Among the echinocandins, micafungin has been studied most extensively. This paper reviews the results from the largest studies of micafungin among patients with invasive and esophageal candidiasis, and supports the use of echinocandins in this increasingly common disorder.